170 related articles for article (PubMed ID: 38315170)
21. Cancer cell-intrinsic expression of MHC II in lung cancer cell lines is actively restricted by MEK/ERK signaling and epigenetic mechanisms.
Neuwelt AJ; Kimball AK; Johnson AM; Arnold BW; Bullock BL; Kaspar RE; Kleczko EK; Kwak JW; Wu MH; Heasley LE; Doebele RC; Li HY; Nemenoff RA; Clambey ET
J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32312906
[TBL] [Abstract][Full Text] [Related]
22. Epigenetic reprogramming by tumor-derived EZH2 gain-of-function mutations promotes aggressive 3D cell morphologies and enhances melanoma tumor growth.
Barsotti AM; Ryskin M; Zhong W; Zhang WG; Giannakou A; Loreth C; Diesl V; Follettie M; Golas J; Lee M; Nichols T; Fan C; Li G; Dann S; Fantin VR; Arndt K; Verhelle D; Rollins RA
Oncotarget; 2015 Feb; 6(5):2928-38. PubMed ID: 25671303
[TBL] [Abstract][Full Text] [Related]
23. Low-dose IFN-gamma induces tumor MHC expression in metastatic malignant melanoma.
Propper DJ; Chao D; Braybrooke JP; Bahl P; Thavasu P; Balkwill F; Turley H; Dobbs N; Gatter K; Talbot DC; Harris AL; Ganesan TS
Clin Cancer Res; 2003 Jan; 9(1):84-92. PubMed ID: 12538455
[TBL] [Abstract][Full Text] [Related]
24. Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy.
Restifo NP; Marincola FM; Kawakami Y; Taubenberger J; Yannelli JR; Rosenberg SA
J Natl Cancer Inst; 1996 Jan; 88(2):100-8. PubMed ID: 8537970
[TBL] [Abstract][Full Text] [Related]
25. Effect of recombinant human leukocyte, fibroblast, and immune interferons on expression of class I and II major histocompatibility complex and invariant chain in early passage human melanoma cells.
Nisticò P; Tecce R; Giacomini P; Cavallari A; D'Agnano I; Fisher PB; Natali PG
Cancer Res; 1990 Dec; 50(23):7422-9. PubMed ID: 1701342
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of TCA cycle improves the anti-PD-1 immunotherapy efficacy in melanoma cells via ATF3-mediated PD-L1 expression and glycolysis.
Liu N; Yan M; Tao Q; Wu J; Chen J; Chen X; Peng C
J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37678921
[TBL] [Abstract][Full Text] [Related]
27. IFN-gamma-induced PD-L1 expression in melanoma depends on p53 expression.
Thiem A; Hesbacher S; Kneitz H; di Primio T; Heppt MV; Hermanns HM; Goebeler M; Meierjohann S; Houben R; Schrama D
J Exp Clin Cancer Res; 2019 Sep; 38(1):397. PubMed ID: 31506076
[TBL] [Abstract][Full Text] [Related]
28. Loss of interferon-gamma inducibility of the MHC class II antigen processing pathway in head and neck cancer: evidence for post-transcriptional as well as epigenetic regulation.
Meissner M; Whiteside TL; van Kuik-Romein P; Valesky EM; van den Elsen PJ; Kaufmann R; Seliger B
Br J Dermatol; 2008 May; 158(5):930-40. PubMed ID: 18284388
[TBL] [Abstract][Full Text] [Related]
29. Glucocorticoid activation by HSD11B1 limits T cell-driven interferon signaling and response to PD-1 blockade in melanoma.
Martins Nascentes Melo L; Herrera-Rios D; Hinze D; Löffek S; Oezel I; Turiello R; Klein J; Leonardelli S; Westedt IV; Al-Matary Y; Egea-Rodriguez S; Brenzel A; Bau M; Sucker A; Hadaschik E; Wirsdörfer F; Hanenberg H; Uhlenbrock N; Rauh D; Poźniak J; Rambow F; Marine JC; Effern M; Glodde N; Schadendorf D; Jablonska J; Hölzel M; Helfrich I
J Immunother Cancer; 2023 Apr; 11(4):. PubMed ID: 37028818
[TBL] [Abstract][Full Text] [Related]
30. Role of EZH2 histone methyltrasferase in melanoma progression and metastasis.
Mahmoud F; Shields B; Makhoul I; Hutchins LF; Shalin SC; Tackett AJ
Cancer Biol Ther; 2016 Jun; 17(6):579-91. PubMed ID: 27105109
[TBL] [Abstract][Full Text] [Related]
31. Resistance to BRAF Inhibitors: EZH2 and Its Downstream Targets as Potential Therapeutic Options in Melanoma.
Uebel A; Kewitz-Hempel S; Willscher E; Gebhardt K; Sunderkötter C; Gerloff D
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768289
[TBL] [Abstract][Full Text] [Related]
32. Nanoparticle delivery of miR-21-3p sensitizes melanoma to anti-PD-1 immunotherapy by promoting ferroptosis.
Guo W; Wu Z; Chen J; Guo S; You W; Wang S; Ma J; Wang H; Wang X; Wang H; Ma J; Yang Y; Tian Y; Shi Q; Gao T; Yi X; Li C
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35738798
[TBL] [Abstract][Full Text] [Related]
33. High GILT Expression and an Active and Intact MHC Class II Antigen Presentation Pathway Are Associated with Improved Survival in Melanoma.
Buetow KH; Meador LR; Menon H; Lu YK; Brill J; Cui H; Roe DJ; DiCaudo DJ; Hastings KT
J Immunol; 2019 Nov; 203(10):2577-2587. PubMed ID: 31591149
[TBL] [Abstract][Full Text] [Related]
34. Mefloquine enhances the efficacy of anti-PD-1 immunotherapy via IFN-γ-STAT1-IRF1-LPCAT3-induced ferroptosis in tumors.
Tao Q; Liu N; Wu J; Chen J; Chen X; Peng C
J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38471712
[TBL] [Abstract][Full Text] [Related]
35. Regulation of the antigenic phenotype of human melanoma cells by recombinant interferons.
Giacomini P; Gambari R; Barbieri R; Nisticò P; Tecce R; Pestka S; Gustafsson K; Natali PG; Fisher PB
Anticancer Res; 1986; 6(5):877-84. PubMed ID: 2432832
[TBL] [Abstract][Full Text] [Related]
36. Microsatellite Instability Predicts Response to Anti-PD1 Immunotherapy in Metastatic Melanoma.
Roncati L
Acta Dermatovenerol Croat; 2018 Dec; 26(4):341-343. PubMed ID: 30665488
[TBL] [Abstract][Full Text] [Related]
37. eEF2K promotes PD-L1 stabilization through inactivating GSK3β in melanoma.
Chen X; Wang K; Jiang S; Sun H; Che X; Zhang M; He J; Wen Y; Liao M; Li X; Zhou X; Song J; Ren X; Yi W; Yang J; Chen X; Yin M; Cheng Y
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35347072
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of interferon-gamma-stimulated melanoma progression by targeting neuronal nitric oxide synthase (nNOS).
Tong S; Cinelli MA; El-Sayed NS; Huang H; Patel A; Silverman RB; Yang S
Sci Rep; 2022 Feb; 12(1):1701. PubMed ID: 35105915
[TBL] [Abstract][Full Text] [Related]
39. Nitric oxide and KLF4 protein epigenetically modify class II transactivator to repress major histocompatibility complex II expression during Mycobacterium bovis bacillus Calmette-Guerin infection.
Ghorpade DS; Holla S; Sinha AY; Alagesan SK; Balaji KN
J Biol Chem; 2013 Jul; 288(28):20592-606. PubMed ID: 23733190
[TBL] [Abstract][Full Text] [Related]
40. Dysregulated recruitment of the histone methyltransferase EZH2 to the class II transactivator (CIITA) promoter IV in breast cancer cells.
Truax AD; Thakkar M; Greer SF
PLoS One; 2012; 7(4):e36013. PubMed ID: 22563434
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
